StockData
NewcelX Ltd. logo

NewcelX Ltd. (NCEL) stock

NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 4/30
$2.54−0.15 (-5.58%)

Close on Nov 20, 2026Market cap $12.19MP/E 1.2Yield –

NewcelX r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $1.13M, up 13.5% from the year before. The highest annual figure on record is $8.98M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.13M+13.5%
FY2024Dec 31, 2024$992.00K-38.3%
FY2023Dec 31, 2023$1.61M-82.1%
FY2022Dec 31, 2022$8.98M+51.6%
FY2021Dec 31, 2021$5.92M+5844.4%
FY2020Dec 31, 2020$99.58K-88.9%
FY2019Dec 31, 2019$897.79K+26.7%
FY2018Dec 31, 2018$708.46K–

More NewcelX figures

See a number that looks wrong?